The global spatial proteomics market size is anticipated to reach USD 199.8 million by 2030 and is projected to grow at a CAGR of 14.76% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing demand for precision medicine and personalized therapies, particularly in oncology. As cancer continues to be one of the leading causes of death worldwide, as per NIH cancer statistics, over 1.9 million new cases were reported in the U.S. in 2023. There is a growing need for advanced technologies that can provide detailed insights into tumor biology and the tumor microenvironment. The growing focus on personalized medicine, advancements in genomics and proteomics, and rising investments in cancer research are key factors fueling the market growth of spatial proteomics over the forecast period.
In addition, spatial proteomics offers a unique advantage by allowing researchers to visualize protein interactions in their native tissue context, enabling the identification of specific biomarkers and therapeutic targets. This technology’s ability to dissect cellular heterogeneity and understand disease mechanisms at a deeper level has led to its adoption in research and drug development, especially for complex diseases like cancer, thus boosting market growth.
Another key driver of the market is the growing investment in proteomics research from both government agencies and private sectors. The aging population and the rising prevalence of chronic diseases, such as cardiovascular diseases, neurodegenerative disorders, and autoimmune diseases, have increased the demand for innovative diagnostic and therapeutic solutions. According to the World Health Organization (WHO), the proportion of people aged 60 years and older is expected to reach 2.1 billion by 2050, driving the need for more advanced technologies like spatial proteomics to develop effective treatments tailored to this patient population. This surge in funding and collaborative efforts between pharmaceutical companies, biotech firms, and academic institutions has accelerated technological advancements and expanded the application of spatial proteomics in various fields beyond oncology.
However, the market faces significant restraints, one of which is the high cost of advanced imaging and mass spectrometry equipment. These instruments require substantial capital investment, making them less accessible to smaller research institutions and laboratories with limited budgets.
Request a free sample copy or view report summary: Spatial Proteomics Market Report
Consumables dominated the product segment with the highest revenue share of 56.26% in 2023. The frequent use of these consumables in various research applications, including cancer studies, genomics, and proteomics, boosts the demand and market share. On the other hand, software is anticipated to grow at the highest CAGR over the forecast period.
Based on technology, imaging-based technologies for spatial proteomics accounted for the largest revenue share in 2023. Imaging-based technologies can be integrated with other platforms, such as genomics and transcriptomics, to provide a more holistic view of biological systems. This integration enhances the ability to correlate protein expression patterns with genetic data, leading to a deeper understanding of disease mechanisms and potential therapeutic targets.
Based on workflow, the instrumental analysis held the largest revenue share of 47.42% in 2023. Technological innovations, such as the integration of artificial intelligence (AI) and automation, are driving the instrumental analysis market by enhancing the speed, efficiency, and accuracy of spatial proteomics experiments. However, sample preparation is projected to witness a significant growth rate over the forecast period.
Based on sample type, the FFPE segment accounted for the largest revenue share in 2023. The use of FFPE samples enables direct correlation between spatial proteomics data and histopathological information, enhancing the understanding of disease mechanisms and tissue architecture, which further drives market growth for this sample type.
Based on end-use, academic & translational research institutes dominated the segment with the largest revenue share of 67.85% in 2023. This is attributed to the advanced studies in cancer research, genomics, and proteomics. On the other hand, pharmaceutical & biotech companies are anticipated to grow at a significant CAGR over the forecast period.
The North American region dominated the market share of 48.97% in 2024 owing to the strong pharmaceutical & biotechnology companies, advanced research institutes, substantial investment in life science R&D, and increasing focus on biologics and personalized medicine. On the other hand, Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.
Grand View Research has segmented the global spatial proteomics market based on product, technology, workflow, sample type, end-use, and region:
Spatial Proteomics Product Outlook (Revenue, USD Billion, 2018 - 2030)
Instruments
Automated
Semi-automated & Manual
Consumables
Software
Spatial Proteomics Technology Outlook (Revenue, USD Billion, 2018 - 2030)
Imaging-based Technologies
Mass Spectrometry-based Technologies
Sequencing-based Technologies
Other Technologies
Spatial Proteomics Workflow Outlook (Revenue, USD Billion, 2018 - 2030)
Sample Preparation
Instrumental Analysis
Data Analysis
Spatial Proteomics Sample Type Outlook (Revenue, USD Billion, 2018 - 2030)
FFPE
Fresh Frozen
Spatial Proteomics End-use Outlook (Revenue, USD Billion, 2018 - 2030)
Academic & Translational Research Institutes
Pharmaceutical And Biotechnology Companies
Other End-use
Spatial Proteomics Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Spatial Proteomics Market
10X genomics
Bruker
Fluidigm Corporation
NanoString Technologies, Inc.
Akoya Biosciences, Inc.
PerkinElmer
Danaher
Biotechne
S2 Genomics, Inc.
Seven Bridges Genomics Inc.
"The quality of research they have done for us has been excellent..."